MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Palbociclib

CAS No. : 571190-30-2

MCE 站：Palbociclib

产品活性：Palbociclib (PD 0332991) 是选择性的 CDK4 和 CDK6 抑制剂，IC₅₀ 分别为11 nM，16 nM。Palbociclib 有潜力用于 ER 阳性和 HER2 阴性乳腺癌的研究。

研究领域：Cell Cycle/DNA Damage

作用靶点：CDK

In Vitro: The IC₅₀ of Palbociclib (PD 0332991) for reduction of retinoblastoma (Rb) phosphorylation at Ser⁷⁸⁰ in MDA-MB-435 breast carcinoma cells is 66 nM. Palbociclib is equally effective at reducing Rb phosphorylation at Ser⁷⁹⁵ in this tumor with an IC₅₀ of 63 nM, and similar effects on both Ser⁷⁸⁰ and Ser⁷⁹⁵ phosphorylation are obtained in the Colo-205 colon carcinoma. The MP-MRT-AN (AN), KP-MRT-RY (RY), G401, and KP-MRT-NS (NS) cell lines are effectively inhibited by Palbociclib (PD) in a concentration-dependent manner in a WST-8 assay. The IC₅₀s are 0.01 ?M, 0.01 ?M, 0.06 ?M, and 0.6 ?M, respectively. In contrast, the KP-MRT-YM (YM) cell line is resistant to Palbociclib (IC₅₀>10 ?M). The flow cytometry results show that Palbociclib at concentrations between 0 to 1.0 ?M induces G1 arrest in the AN, RY, G401 and NS cell lines in a concentration-dependent manner, but has no effect on YM cells. The BrdU incorporation results are consistent with the WST-8 and flow cytometry results: PD reduces BrdU incorporation (indicating G1 arrest) in the AN, RY, G401 and NS cell lines, but not in the YM cell line. Palbociclib, even at a concentration of 0.05 ?M, significantly reduces BrdU incorporation in the AN, RY, and G401 cell lines (p<0.05).

In Vivo: Palbociclib (PD 0332991) exhibits significant antitumor efficacy against multiple human tumor xenograft models. In mice bearing Colo-205 colon carcinoma xenografts (p16 deleted), daily p.o. dosing for 14 days with Palbociclib (150 or 75 mg/kg) produces rapid tumor regressions and a corresponding tumor growth delay of ~50 days with >1 log of tumor cell kill at the highest dose tested. At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at doses as low as 12.5 mg/kg, a 13-day growth delay is obtained indicating a 90% inhibition of tumor growth rate. Likewise, robust antitumor activity is seen in the MDA-MB-435 breast carcinoma (p16 deleted) where complete tumor stasis is apparent at 150 mg/kg and some cell kill is evident at the highest dose.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  Bioactive Compound Library Plus  |  Peptidomimetic Library  |  Ro-3306  |  Seliciclib  |  Flavopiridol  |  NVP-2  |  SNS-032  |  AZD-5438  |  Kenpaullone  |  GSK 3 Inhibitor IX  |  AUZ 454  |  XL413 hydrochloride  |  CGP60474  |  Wogonin  |  CVT-313  |  NG 52  |  BMS-265246  |  (R)-CR8 trihydrochloride  |  R547  |  PHA-767491 hydrochloride  |  CDK12-IN-3  |  KH-CB19  |  CDK2-IN-4  |  Purvalanol A  |  Cucurbitacin E  |  THZ1-R  |  FMF-04-159-2  |  LY2857785  |  CP-10  |  ML167

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。